Yahoo
ASX - Delayed Quote AUD

Racura Oncology Ltd (RAC.AX)

1.4750 -0.0050 (-0.34%)
At close: November 6 at 4:10:28 PM GMT+11
Chart Range Bar
Loading chart for RAC.AX
  • Previous Close 1.4800
  • Open 1.4800
  • Bid 1.4650 x --
  • Ask 1.4800 x --
  • Day's Range 1.4200 - 1.4800
  • 52 Week Range 1.4000 - 3.7900
  • Volume 143,510
  • Avg. Volume 80,903
  • Market Cap (intraday) 289.202M
  • Beta (5Y Monthly) 0.97
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0600
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.

racuraoncology.com

--

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

RAC.AX
45.97%
S&P/ASX 200 [XJO] (^AXJO)
3.52%

1-Year Return

RAC.AX
51.80%
S&P/ASX 200 [XJO] (^AXJO)
2.86%

3-Year Return

RAC.AX
45.32%
S&P/ASX 200 [XJO] (^AXJO)
29.29%

5-Year Return

RAC.AX
57.12%
S&P/ASX 200 [XJO] (^AXJO)
20.97%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -23.40%

  • Return on Equity (ttm)

    -42.28%

  • Revenue (ttm)

    2.81M

  • Net Income Avi to Common (ttm)

    -11.09M

  • Diluted EPS (ttm)

    -0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    34.29M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.92M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: